The role of opioid antagonist efficacy and constitutive opioid receptor activity in the opioid withdrawal syndrome in mice

Pharmacology Biochemistry and Behavior

Volumn 99, Issue 4, 2011, Pages 671-675

  Navani, Dipesh M ^a   Sirohi, Sunil ^a   Madia, Priyanka A ^a   Yoburn, Byron C ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

6 naltrexol; Constitutive receptor activity; Dependence; Inverse opioid agonist; Morphine; Naltrexone; Neutral opioid antagonist; Withdrawal

Indexed keywords

MORPHINE; NALTREXOL; NALTREXONE; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; LOW DRUG DOSE; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; OPIATE WITHDRAWAL SYNDROME; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MORPHINE DEPENDENCE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; RECEPTORS, OPIOID; SUBSTANCE WITHDRAWAL SYNDROME;

MUS;

EID: 79960318261     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2011.06.025     Document Type: Article

References (23)

1. J.U. Adams, and S.G. Holtzman Pharmacologic characterization of the sensitization to the rate-decreasing effects of naltrexone induced by acute opioid pretreatment in rats J Pharmacol Exp Ther 253 1990 483 489 (Pubitemid 20181686)
2. T. Avidor-Reiss, M. Bayewitch, R. Levy, N. Matus-Leibovitch, I. Nevo, and Z. Vogel Adenylylcyclase supersensitization in μ-opioid receptor-transfected Chinese hamster ovary cells following chronic opioid treatment J Biol Chem 270 1995 29732 29738
3. M.R. Azar, B.C. Jones, and G. Schulteis Conditioned place aversion is a highly sensitive index of acute opioid dependence and withdrawal Psychopharmacology (Berl) 170 2003 42 50 (Pubitemid 37372477)
4. T. Costa, and A. Herz Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins Proc Natl Acad Sci U S A 86 1989 7321 7325 (Pubitemid 19254452)
5. D.J. Finney Probit analysis 3rd ed. 1973 Cambridge University Press London
6. T. Kenakin Inverse, protean, and ligand-selective agonism: matters of receptor conformation FASEB J 15 2001 598 611 (Pubitemid 32245978)
7. J.G. Liu, and P.L. Prather Chronic exposure to μ-opioid agonists produces constitutive activation of μ-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment Mol Pharmacol 60 2001 53 62 (Pubitemid 32595233)
8. G. Milligan, D.J. MacEwan, M. Mercouris, and I. Mullaney Inverse agonism at adrenergic and opioid receptors: studies with wild type and constitutively active mutant receptors Receptors Channels 5 1997 209 213 (Pubitemid 28242959)
9. P.L. Prather Inverse agonists: tools to reveal ligand-specific conformations of G protein-coupled receptors Sci STKE 2004 2004:pe1.
10. K.M. Raehal, J.J. Lowery, C.M. Bhamidipati, R.M. Paolino, J.R. Blair, and D. Wang In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice J Pharmacol Exp Ther 313 2005 1150 1162 (Pubitemid 40727018)
11. W. Sadée, D. Wang, and E.J. Bilsky Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities Life Sci 76 2005 1427 1437 (Pubitemid 40164772)
12. G. Schulteis, J. Liu, N. Amitai, and S. Tzeng Context- and cue-conditioned potentiation of acute morphine dependence and withdrawal Pharmacol Biochem Behav 82 2005 82 89 (Pubitemid 41423490)
13. G. Schulteis, D. Chiang, and C. Archer Relative potency of the opioid antagonists naloxone and 6-alpha-naloxol to precipitate withdrawal from acute morphine dependence varies with time post-antagonist Pharmacol Biochem Behav 92 2009 157 163
14. S.K. Sharma, W.A. Klee, and M. Nirenberg Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance Proc Natl Acad Sci U S A 72 1975 3092 3096
15. S. Sirohi, P. Kumar, and B.C. Yoburn μ-Opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy J Pharmacol Exp Ther 323 2007 701 707 (Pubitemid 350005140)
16. S. Sirohi, S.V. Dighe, P.A. Madia, and B.C. Yoburn The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity J Pharmacol Exp Ther 330 2009 513 519
17. E.L. van Dorp, A. Yassen, and A. Dahan Naloxone treatment in opioid addiction: the risks and benefits Expert Opin Drug Saf 6 2007 125 132 (Pubitemid 46380806)
18. J.E. Villarreal, and A. Castro A reformulation of the dual-action model of opioid dependence: opioid-specific neuronal kindling [proceedings] Psychopharmacol Bull 17 1981 56 58 (Pubitemid 11180471)
19. E.A. Walker, and S.N. Sterious Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence Br J Pharmacol 145 2005 975 983 (Pubitemid 41129019)
20. Z. Wang, E.J. Bilsky, F. Porreca, and W. Sadée Constitutive μ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence Life Sci 54 1994 PL339 PL350
21. D. Wang, K.M. Raehal, E.J. Bilsky, and W. Sadée Inverse agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence J Neurochem 77 2001 1590 1600 (Pubitemid 32574494)
22. D. Wang, K.M. Raehal, E.T. Lin, J.J. Lowery, B.L. Kieffer, and E.J. Bilsky Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence J Pharmacol Exp Ther 308 2004 512 520 (Pubitemid 38134212)
23. E.L. Way, H.H. Loh, and F.H. Shen Simultaneous quantitative assessment of morphine tolerance and physical dependence J Pharmacol Exp Ther 167 1969 1 8